Daniel Ter-Minassian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Ter-Minassian has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bertrand Lell
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
1 shared publication - Carmen Lucelly Ospina Salazar
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
1 shared publication - Christian Supan
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
1 shared publication - Ghyslain Mombo-Ngoma
German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riems
1 shared publication - Maryvonne Kombila
Département de Parasitologie-Mycologie, Faculté de Médecine, Université des Sciences de la Santé, Libreville, Gabon
1 shared publication - Matthias P. Dal-Bianco
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
1 shared publication
Latest Publications
- Open Access
- 1 March 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 53
Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
Background: The development and spread of drug resistantPlasmodium falciparumstrains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitiveP. falciparumlaboratory strains.Methods: Adult young male aged 18 to 45 years, asymptomatic carriers ofP. falciparum, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male withP. falciparuminfection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.
- 1 March 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 53
Open AccessPhase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
Background: The development and spread of drug resistantPlasmodium falciparumstrains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitiveP. falciparumlaboratory strains.Methods: Adult young male aged 18 to 45 years, asymptomatic carriers ofP. falciparum, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male withP. falciparuminfection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.